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Background: Recently, with the access of low toxicity biological and targeted therapies, evidence of the existence
of a long-term survival subpopulation of cancer patients is appearing. We have studied an unselected population
with advanced lung cancer to look for evidence of multimodality in survival distribution, and estimate the proportion
of long-term survivors.
Methods: We used survival data of 4944 patients with non-small-cell lung cancer (NSCLC) stages IIIb–IV at diagnostic,
registered in the National Cancer Registry of Cuba (NCRC) between January 1998 and December 2006. We fitted
one-component survival model and two-component mixture models to identify short- and long- term survivors.
Bayesian information criterion was used for model selection.
Results: For all of the selected parametric distributions the two components model presented the best fit. The
population with short-term survival (almost 4 months median survival) represented 64% of patients. The population of
long-term survival included 35% of patients, and showed a median survival around 12 months. None of the patients of
short-term survival was still alive at month 24, while 10% of the patients of long-term survival died afterwards.
Conclusions: There is a subgroup showing long-term evolution among patients with advanced lung cancer. As survival
rates continue to improve with the new generation of therapies, prognostic models considering short- and long-term
survival subpopulations should be considered in clinical research.
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For decades, the primary focus of cancer research was
the development of therapeutic interventions to cure the
cancer or produce a remission. Success with standard
cancer therapy (surgery, radiotherapy and chemotherapy
combinations) was mainly limited to early stage tumors.
Because of the natural history of cancer, it is relevant to
understand if we are witnessing real cures, or just delays* Correspondence: lsanchez@cim.sld.cu; lage@cim.sld.cu
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Survival analysis addresses such issues.
The relative survival curve for many cancers will reach
a plateau some years after diagnosis, indicating that the
mortality among patients still alive at that point is near
to the expected mortality in the general population [2].
A straightforward way to identify whether a particular
dataset might include a subset of long-term survivors is
thus to look at the survival curve to identify the exist-
ence or not of such plateau [3]. Another approach is to
perform a visual inspection of the hazard function (in-
stantaneous risk of death) plot to look for temporal
changes suggesting a “cure” might have been achieved
for some patients [4].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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comes (overall survival and/or progression-free survival)
are estimated from conventional methods as Kaplan-Meier
and Cox regression models. However, these methods
might fail to describe adequately the heterogeneity among
cancer patients [5]. To overcome that drawback Boag [6]
proposed a two-component mixture model for the analysis
of survival data when it is known that a proportion of pa-
tients are cured. Such cure models, explicitly model sur-
vival as a mixture of cured patients (usually modeled using
logistic regression approaches) and non-cured patients
(usually modeled using survival approaches).
Many variations of cure models have been proposed
and extensively applied. However, the applications have
been mainly for patients diagnosed at early stages of
cancer [7-11]. Almost all reports have used simulated
data or have applied the different models to breast or
colon cancer in curable stages.
Exploration of survival data looking for a “cured frac-
tion” has not been extensively applied for advanced can-
cer, where clinical experience indicates that “cures” are
extremely rare or even do not exist. Particularly in lung
cancer, without curative treatments for patients in ad-
vanced stages, few studies have reported applications of
mixture cure models [12].
Recently, and because the advent of biological therapies
presenting low toxicity, and targeted therapies, evidences
of the existence of a long-term survival subpopulation of
patients are beginning to appear, and it is thus relevant to
know if this subpopulation represents the tail of the sur-
vival distribution that have been shifted towards longer
survival by the therapy being administered, or if it repre-
sents the existence of intrinsic heterogeneity in the patient
population, causing multimodality in the distribution of
survival times. If such a chronic evolution subpopulation
exists, even in the advanced cancer situation, and some pa-
tients live enough to allow the intervention of competing
causes of death, it could be convenient to think in terms of
long-term survivors or “statistically” cured patients [13].
Finally, it should be noted that the presence of multi-
modality or mixture distributions in cancer patients could
be obscured when clinical trials are the main data source
for the analysis, because patients included in clinical trials
are by definition selected for reduction of heterogeneity.
In the present paper several parametric survival models
and mixture models were applied to an unselected popula-
tion of patients with advanced lung cancer to look for evi-
dence of multimodality in the survival distribution, and to
estimate the proportion of long-term survivors.
Methods
Data
The NCRC registers all cancers diagnosed in Cuba [14].
Information within cancer registrations is ascertainedfrom hospital records, diagnostic procedures, pathology
reports and death certificates. The estimate of registration
completeness at NCRC is 80% [15]. Incident cases of
NSCLC reported by NCRC were linked to death records
provided by the Cuban National Statistics Office of the
Ministry of Public Health.
All adults over 18 years, diagnosed with histological or
cytological proven non-small-cell lung cancer (NSCLC)
at stages IIIb or IV between January 1998 and December
2006, who were registered in the National Cancer Regis-
try of Cuba (NCRC) with follow-up to December 31,
2010 were eligible for analysis. Of the 6425 eligible pa-
tients, 4944 (76.9%) were linked with death records using
personal identification number. Due to missing or incor-
rect identification, 11.2% of patients were excluded from
the analysis. The rest of the patients (11.9%) were classi-
fied as loss of follow up and were also excluded.
Modeling approach
For the one component model, the survival function S(t)
for the overall population survival time and the hazard, the
instantaneous risk of death, were fitted assuming the fol-
lowing parametric models: Gaussian, Log-normal, Weibull
and Gamma. Additionally, we fitted a two-component
mixture model considering the same distributions ad-
justed to identify short- and long- term survivors within
the advanced lung cancer patients. The survival function
for overall population survival time T was expressed as:
S tð Þ ¼ c1G t j μ1; σ1ð Þ þ c2G t j μ2; σ2ð Þ
Where G(t | μ, σ) is a distribution function. The param-
eters ck, (k = 1, 2), with the restriction that 0 < c1 < c2 ≤ 1
and c1 + c2 = 1, are the mixed fractions for the K popula-
tion. The fractions c1 and c2 can be interpreted as the
proportion of short-term and long-term survivors respect-
ively. In the model (μk, σk), are the parameters of the para-
metric distribution G.
The maximum likelihood estimators of the parameters
(c, μ, σ) for the one component or two component mix-
ture models were found by maximizing the likelihood
function. We used R v3.0.2 (R Core Team, 2013) for the
statistical analyses with the EM algorithm implemented in
the “rebmix” library [15] of R (R software; http://www.r-
project.org).
Model selection
We compared the parametric models with the Bayesian
information criterion (BIC = −Log likelihodð Þ þ p2 log nð Þ,
where p is the number of parameters and n is the sample
size) to find the most probable model given the data. The
model with the smallest BIC value was considered the best
fit to the observed data. A BIC difference > 10 between the
more complex model assuming two components and the
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as very strong evidence to support the two components
approach against the simplest alternative [16].
Ethics
The use of the data here reported was approved for re-
search purposes by the appropriate Ethical and Research
Commitee of the National Cancer Registry of Cuba.
Anonymized records (non-patient identifiable data) were
provided by the NCRC.
Results
The median survival time of the Cuban advanced NSCLC
patients was 3.93 months. Note that in the survival curve
(Figure 1a) it is possible to distinguish a plateau at the end
of the study period. Accordingly, the hazard function
(Figure 1b) shows a monotonic decreasing curve. Both
graphics suggest the presence of two different populations.
For all of the selected parametric distributions (Gaussian,
log-normal, Weibull or Gamma), the two components
model presented the best fit. Gaussian distribution showed
the greatest changes in BIC values, while the Gamma dis-
tribution provided the best fit to the data (see Table 1). In
all models the BIC difference between one- and two-
component models was greater than 10, supporting the
most complex model and thus the likely existence of
two populations of patients. In the Gamma model, theFigure 1 Cumulative survival a) and hazard curves b) for advanced no
Registry. 1998–2006.population with short term survival (almost 4 months me-
dian survival) represented 64% of NSCLC patients. The
population of long-term survivors, which included 35% of
patients, showed a median survival close to 12 months.
Models assuming Gaussian and Gamma distributions
were selected to illustrate the density and cumulative
survival curves for short-term and long-term survival
populations (Figure 2). Figure 2a and d show the density
functions for Gaussian and Gamma distribution respect-
ively. The density peak at 4 months for the first popula-
tion, indicates that most patients died at that moment.
However in the second population the density is flat-
tened. Figure 2b shows no survivors after 11 month for
short-term survival population whereas 45% of long-
term survival population is still alive. Nevertheless, as-
suming Gamma distribution (Figure 2e), no patients of
the first population are still surviving at month 24, while
10% of long-term survival population died afterwards.
As seen, the mixture curves, either for Gaussian or for
Gamma distributions, fit quite well the observed survival
(Figure 2c, f ).
Discussion
Is there a subgroup with long-term survival among pa-
tients with advanced lung cancer? Our data suggest an af-
firmative answer. The survival data of advanced NSCLC
patients reported by the NCRC could be best explained byn-small cell lung cancer registry by the Cuban Cancer National
Table 1 Mix fraction and median survival times estimated












c Median c Median
Gaussian One 1 7.21 - 36622.4
Two 0.80 3.86 0.20 19.9 31353.9
Weibull One 1 8.27 - 30320.8
Two 0.92 9.17 0.08 10.10 29528.7
Log normal One 1 4.52 - 29094.0
Two 0.77 4.22 0.23 6.57 28942.5
Gamma One 1 7.25 - 29250.5
Two 0.64 3.57 0.35 11.9 28610.3
c, Mix fraction in the total population; BIC, Bayesian information criterion. The
model with the smallest value of BIC has the best fit.
Figure 2 Illustration of survival patterns of short-term, long-term and
distribution b) Cumulative survival curves for short-term, long-term and mi
survival assuming mixture of two Gaussian distributions d) Density survival
short-term, long-term and mixture assuming Gamma distribution f) Observ
distributions.
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simpler model assuming only one homogeneous popula-
tion. In summary, the results provides evidence of the ex-
istence of a mixture of populations, including one with
long-term survival, consisting of more than 10% of all re-
ported cases, with a survival time greater than 24 months.
Therapies for certain cancer types are believed to in-
duce a subset of long term survivors, such as melanoma
[17], breast cancer [18] and multiple myeloma [3]. On
the other hand, population based studies have reported
the cure fraction estimates for breast [5,12,19] and colo-
rectal cancer [13,20]. However, to our knowledge, this is
the first study in an unselected population with advanced
NSCLC patients that has found compelling evidence of
the existence of a subgroup of patients presenting long-
term evolution.
In spite of the fitting complexity of the mixture model,
its parameters have a very intuitive interpretation for cli-
nicians. Each subpopulation can be distinguished by two
attributes: its size or mix fraction, expressed in percent-
age; and the corresponding median survival time. It ismixture populations. a) Density survival curves assuming Gaussian
xture assuming Gaussian distribution c) Observed vs estimated overall
curves assuming Gamma distribution e) Cumulative survival curves for
ed vs estimated overall survival assuming mixture of two Gamma
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very sensitive to the parametric distribution chosen to
work with. Sometimes, the distribution may not be flexible
enough to capture the overall shape of the survival distri-
bution [13]. For this reason, the selection of the paramet-
ric distribution to model the observed data should be
done carefully. McCullagh and Barry [21] proposed a
model selection process algorithm and recommended to
fit different distributions to the data to select the best one
by using one of the available information criteria.
There are some limitations to both the data and the
methodology used in this study. The completeness of
NCRC data is known to be high, but may be biased by
uncorrected diagnosis dates. Some studies have found
this issue to have minimal impact on survival [22].
Stage-specific cure has rarely been estimated due the
large proportion of cancer without code of stage in
population-based data. Another possible source of bias
is that patients without death certificate were excluded
from the analysis. As a consequence, under-estimation of
survival rates could have happened. However, studies aims
to measure that bias, concluded that the effect is minimal
when data from population-based cancer registry is used,
indicating that the losses can be considered practically
random [23,24]. Furthermore, Yu [20] emphasizes that
mixture cure models should be used when there is suffi-
cient follow-up beyond the time when most events occurs.
In the case of advanced NSCLC, although estimated me-
dian survivals are in the range of 8 to 10 months, several
reports [25-27] support the existence of long term survi-
vors - defined as those surviving for more than 2 years
after a diagnosis of extensive NSCLC [28].
The transition of advanced cancer to chronicity is a
concept that has recently emerged in the literature. Re-
search in cancer treatment has been focused on the
search for “cures”, in a naïve extrapolation of the success
of antibiotics against infections. This therapeutic paradigm
is currently in change driven by the success of modern
treatments in prolonging survival in patients with ad-
vanced cancer with an ethically acceptable quality of life
[29-31], and thus research focus is also moving towards
the long term control of the advanced disease. As an ana-
logy worth to note, the history of therapeutic research in
Type 1 Diabetes run exactly in the opposite way: whereas
it started looking for long term control, and remained so
for decades, the therapeutic shift to its “cure” has only be-
come a focus of attention, through the current experimen-
tal technologies of pancreatic islet transplants.
Despite their theoretical appearance, these intellectual
frames can have huge practical implications for the way
clinical research is designed and analyzed. The importance
of accounting for long term survivors when the efficacy
and safety of immune-oncologic agents is evaluated has
been highlighted before [32]. The log rank test and Coxregression models, the standard analyses in immunother-
apy evaluation, have maximal statistical power under the
proportional hazard assumption. However, Cox models
can only provide a satisfactory description of relative sur-
vival of the various population groups in the early years
after treatment begins, as they cannot present a plateau.
Moreover, as survival rates continue to improve, long term
survival and cure are becoming increasingly important
endpoints when planning oncological clinical trials.
Further research
Further research is needed to explore the effect of indi-
vidual prognostic factors and the effect of treatments on
the proportion and the failure time of long-term and
short-term survival patients. Few current clinical trials
have been designed and consequently analyzed with that
perspective. Systematic analysis of heterogeneity in sur-
vival curves, and of the impact of treatments, not just in
the attributes of the survival curves, but on the internal
distribution of survival subpopulations, could provide
novel and fertile avenues of research.
Conclusions
This study analysed the survival distribution of advanced
NSCLC patients registered in the NCRC. It provides evi-
dence of the existence of a mixture of populations, in-
cluding a subgroup showing long-term evolution. As
survival rates continue to improve with the new gener-
ation of therapies, prognostic models considering short-
and long- term survival subpopulation should be consid-
ered in clinical research. Be able to increase the propor-
tion of patients in the long- term survival group could
be a desirable goal for cancer control programs.
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